Prepare your AAV and LVV production processes for in vivo delivery
Explore the manufacturing decisions shaping in vivo advanced therapies, from producer cell lines and scale-up to purification and analytical testing.

Download The Vector Revolution
Understand what changes when viral vectors become in vivo medicines
Direct patient administration brings stricter purity expectations and new demands for process control. In this white paper, AGC Biologics experts Silvia Ungari and Chiara Boroni explain how upstream development, downstream purification, and analytical characterization are evolving for in vivo lentiviral vector (LVV) and adeno-associated viral vector (AAV) applications.
Use their insights to inform your scale-up strategy, evaluate emerging producer cell platforms and identify the manufacturing capabilities your program needs as it advances toward patient delivery.
What you will explore:
-
Ex vivo and in vivo differences in purity, quality, and production scale for lentiviral and adeno-associated viral vectors
-
Seed train, transfection, and facility considerations for large-scale production
-
Stable producer cell lines and their analytical trade-offs
-
Vector design and manufacturing strategies to address immunogenicity
-
LVV purification and AAV full/empty capsid separation
-
Emerging analytical methods and considerations when choosing a CDMO
Meet your viral vector experts
Silvia Ungari
Upstream Vector Development Manager, AGC Biologics
Draw on Silvia's experience in the design, optimization and scale-up of LVV and AAV production processes. In the white paper, Silvia examines large-scale manufacturing, producer cell platforms, immunogenicity and downstream purification.
Chiara Boroni
Analytical Methods Development Manager, AGC Biologics
Explore Chiara's perspective on analytical methods for viral vector identity, safety, purity and potency. The white paper examines the characterization and testing strategies you need to consider for in vivo LVV and AAV processes.
